Abcam PLC
LSE:ABC

Watchlist Manager
Abcam PLC Logo
Abcam PLC
LSE:ABC
Watchlist
Price: 1 226 GBX 11.15% Market Closed
Market Cap: 2.8B GBX

Abcam PLC
Cash from Operating Activities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Abcam PLC
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Abcam PLC
LSE:ABC
Cash from Operating Activities
ÂŁ126m
CAGR 3-Years
22%
CAGR 5-Years
14%
CAGR 10-Years
18%
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Cash from Operating Activities
-$142.1m
CAGR 3-Years
-2%
CAGR 5-Years
-89%
CAGR 10-Years
N/A
Autolus Therapeutics PLC
NASDAQ:AUTL
Cash from Operating Activities
-$254.2m
CAGR 3-Years
-33%
CAGR 5-Years
-16%
CAGR 10-Years
N/A
Immunocore Holdings PLC
NASDAQ:IMCR
Cash from Operating Activities
ÂŁ26.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
Cash from Operating Activities
ÂŁ67.2m
CAGR 3-Years
25%
CAGR 5-Years
2%
CAGR 10-Years
7%
Oxford BioMedica PLC
LSE:OXB
Cash from Operating Activities
-ÂŁ7.8m
CAGR 3-Years
28%
CAGR 5-Years
-6%
CAGR 10-Years
3%
No Stocks Found

Abcam PLC
Glance View

Market Cap
2.8B GBX
Industry
Biotechnology

In the bustling realm of the life sciences, Abcam PLC has carved out a distinct niche as a leading provider of research tools and reagents that are fundamental to scientific discovery and innovation. Born in the vibrant academic environment of Cambridge, England, Abcam was founded in 1998 by Jonathan Milner and a small group of fellow scientists frustrated by the lack of quality and reliability in antibody products. The company’s vision was to fuel research globally by providing a reliable source of quality antibodies, knocking down barriers faced by researchers. From this germ of an idea grew Abcam’s expansive catalog, housing an impressive array of antibodies, proteins, reagents, and assays. These tools have become essential in the pursuit of breakthroughs in fields such as cancer research, drug development, and diagnostics. Abcam thrives on a business model that combines product innovation with an e-commerce platform that connects it to a global customer base of researchers and institutions. By meticulously validating the performance of their products, the company ensures that researchers can rely on the tools to deliver precise and reproducible results. This commitment to quality has fostered a level of trust that underpins the company’s growth. Abcam's revenues primarily stem from sales of its proprietary products alongside a curated selection from third-party vendors. The firm also invests significantly in understanding the evolving needs of the scientific community, tailoring its offerings to support cutting-edge research. This client-centric approach, coupled with their robust online presence, has facilitated Abcam’s expansion far beyond its roots, transforming it into a key player that supports scientific advancement globally.

ABC Intrinsic Value
Not Available

See Also

What is Abcam PLC's Cash from Operating Activities?
Cash from Operating Activities
126m GBP

Based on the financial report for Jun 30, 2022, Abcam PLC's Cash from Operating Activities amounts to 126m GBP.

What is Abcam PLC's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
18%

Over the last year, the Cash from Operating Activities growth was 75%. The average annual Cash from Operating Activities growth rates for Abcam PLC have been 22% over the past three years , 14% over the past five years , and 18% over the past ten years .

Back to Top